Clinical Trials Directory

Trials / Completed

CompletedNCT04703049

The Effect of Whole Blood Viscosity on Contrast-Induced Nephropathy Development in Patients Undergoing Percutaneous Coronary Intervention

The Effect of Whole Blood Viscosity on Contrast-Induced Nephropathy Development in Patients Undergoing Elective Percutaneous Coronary Intervention

Status
Completed
Phase
Study type
Observational
Enrollment
500 (actual)
Sponsor
Bursa Postgraduate Hospital · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

In our study, we aimed to investigate how whole blood viscosity (WBV) affects the development of contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary intervention (PCI).

Detailed description

In our study, 500 patients who applied to the cardiology clinic and underwent PCI for elective procedure, ST segment elevation myocardial infarction (STEMI), and non-STEMI were prospectively included. Before the procedure, we calculated WBV using the formula \[(0.12 × hematocrit) + (0.17 × (total protein - 2.07)\]. We defined CIN as the absolute (≥0.5 mg/dl) or relative increase (≥25%) in serum creatinine 48-72 h after exposure to a contrast agent compared with baseline serum creatinine values.

Conditions

Interventions

TypeNameDescription
OTHERBlood Viscosity Testingwe calculated WBV using the formula \[(0.12 × hematocrit) + (0.17 × (total protein - 2.07)\]. We defined CIN as the absolute (≥0.5 mg/dl) or relative increase (≥25%) in serum creatinine 48-72 h after exposure to a contrast agent compared with baseline serum creatinine values.

Timeline

Start date
2017-07-10
Primary completion
2017-10-31
Completion
2017-11-30
First posted
2021-01-11
Last updated
2021-08-13

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT04703049. Inclusion in this directory is not an endorsement.

The Effect of Whole Blood Viscosity on Contrast-Induced Nephropathy Development in Patients Undergoing Percutaneous Coro (NCT04703049) · Clinical Trials Directory